A composition comprising, separately or together: a component (A) that is an adenosine A2a receptor agonist as defined in the specification； and a component (B) that is one or more compounds selected from: (i) a corticosteroid, (ii) a beta-2 adrenoceptor agonist, (iii) an antimuscarinic agent, (iv) an A2B antagonist, (v) an antihistamine, (vi) a caspase inhibitor, (vii) an ENaC inhibitor, (viii) an LTB4 antagonist, (ix) an LTD4 antagonist, (x) a serine protease inhibitor, (xi) a PDE4 inhibitor and (xii) a dual-acting beta-2 adrenoceptor agonist/muscarinic antagonist, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
